Stock comparison
Eli Lilly
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 72B | Tie |
| Benjamin Graham | 86A | 75B | LLY |
| Philip Fisher | 86A | 75B | LLY |
| Peter Lynch | 74B | 58C | LLY |
| Joel Greenblatt | 78C | 47D | LLY |
| Charlie Munger | 85A | 69B | LLY |
| Terry Smith | 77C | 73B | LLY |
Side-by-side metrics
| Metric | LLY | RMD |
|---|---|---|
| Market cap | $1T | $30.31B |
| P/E (TTM) | 36.6x | 19.6x |
| EV/EBIT | 34.1x | 17.1x |
| ROIC (TTM) | 32.06% | 19.63% |
| Gross margin | 83.51% | 61.69% |
| Net margin | 34.98% | 27.44% |
| Revenue CAGR 5y | 23.17% | 12.64% |
| EPS CAGR 5y | 40.81% | 30.73% |
| Debt / Equity | 1.4x | 0.1x |
| Dividend yield | 0.62% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Market cap$1Tvs $30.31B+97%
- Revenue CAGR 5y23.17%vs 12.64%+45%
- ROIC (TTM)32.06%vs 19.63%+39%
- Gross margin83.51%vs 61.69%+26%
RMD leads on
- Debt / Equity0.1xvs 1.4x+91%
- EV/EBIT17.1xvs 34.1x+50%
- P/E (TTM)19.6xvs 36.6x+46%
- Dividend yield1.14%vs 0.62%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.